Director/PDMR Shareholding

BioVentix PLC
29 January 2024
 

Bioventix plc

 

("Bioventix" or "the Company")

 

Director Dealing

 

Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that the Company was notified today that on 29 January 2024 Peter Harrison, Chief Executive Officer of the Company, sold 62,000 ordinary shares of 5 pence each in the Company ("Ordinary Shares"), at a price of 4,200 pence per Ordinary Share (the "Sale").

 

The Sale was facilitated to enable a new institutional investor to join the share register. Peter Harrison has undertaken not to dispose of any further Ordinary Shares for 12 months.

 

Following the Sale, Peter Harrison has a beneficial interest in 297,088 Ordinary Shares, representing approximately 5.7 per cent. of the issued share capital of the Company.

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details.

 

 

For further information please contact:

 

Bioventix plc

Peter Harrison

Bruce Hiscock

 

Chief Executive Officer

Chief Financial Officer

Tel: 01252 728 001

 

 

 

Cavendish Capital Markets Limited

Geoff Nash / Simon Hicks

Nigel Birks / Harriet Ward

 

Corporate Finance

Corporate Broking

Tel: 020 7220 0500

 

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Peter Harrison

2.

Reason for the Notification

a)

Position/status

Chief Executive Officer

b)

Initial notification/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Bioventix plc

b)

LEI

213800225MHX7LZQY108

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary Shares of 5 pence each

Identification code

GB00B4QVDF07

b)

Nature of the transaction

Sale of Ordinary Shares

c)

Price(s) and volume(s)

62,000 Ordinary Shares

4,200 pence

d)

Aggregated information:

 

·     Aggregated volume

 

·     Price

Sale of 62,000 Ordinary Shares at 4,200 pence each

e)

Date of the transaction

29 January 2024

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

Bioventix (BVXP)
UK 100

Latest directors dealings